Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMoclobemide
说明： Reversible MAO-A inhibitor
化学名： 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide
纯度： ≥99% (HPLC)
生物活性 for Moclobemide
Moclobemide is a reversible monoamine oxidase A (MOA-A) inhibitor.
化合物库 for Moclobemide
Moclobemide is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for Moclobemide
| 分子量 | 268.74 |
| 公式 | C13H17ClN2O2 |
| 储存 | Store at RT |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 71320-77-9 |
| PubChem ID | 4235 |
| InChI Key | YHXISWVBGDMDLQ-UHFFFAOYSA-N |
| Smiles | O=C(NCCN2CCOCC2)C1=CC=C(Cl)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Moclobemide
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 26.87 | 100 | |
| ethanol | 26.87 | 100 |
制备储备液 for Moclobemide
以下数据基于产品分子量 268.74。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.72 mL | 18.61 mL | 37.21 mL |
| 5 mM | 0.74 mL | 3.72 mL | 7.44 mL |
| 10 mM | 0.37 mL | 1.86 mL | 3.72 mL |
| 50 mM | 0.07 mL | 0.37 mL | 0.74 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Moclobemide
参考文献 for Moclobemide
参考文献是支持产品生物活性的出版物。
Merck Index 12 6309
Burkard et al (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 391 PMID: 2913284
Prada et al (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J.Pharmacol.Exp.Ther. 248 400 PMID: 2783611
If you know of a relevant reference for Moclobemide, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: Moclobemide, Moclobemide supplier, reversible, monoamine, oxidase, a, moa-a, inhibitors, inhibits, Monoamine, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 4395, Tocris Bioscience
1 篇 Moclobemide 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Moclobemide 的部分引用包括：
Ulferts et al (2016) Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob Agents Chemother 60 2627 PMID: 26856848
您是否知道使用了 Tocris Moclobemide 的优秀论文？ 请告知我们.
Moclobemide 的评论
目前没有该产品的评论。 Be the first to review Moclobemide and earn rewards!
Have you used Moclobemide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.